Abonnez-vous à la newsletter :
Utilisez la recherche :
Stratégie Sectorielle : Soins de santé
Dividendes et valorisation des principales sociétés cotées européennes des soins de santé.
- Vous n’êtes pas identifié.
-
Stratégie Sectorielle
Soins de santé
Méga capitalisations boursières4 (Cap. ≥ 200 Md€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
 | Roche Holding | 213,8 | 3,1% | 22,8 | 1,0 | 275,6 | -20% | 3% | Drug Manufacturers - Major |
| Roche Holding | 213,8 | 3,1% | 22,7 | 1,0 | 276,3 | -22% | 3% | Drug Manufacturers - Major |
Grosses capitalisations boursières4 (200 Md€ > Cap. ≥ 10 Md€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | 185,8 | 3,1% | 17,1 | 1,0 | 90,2 | -30% | 2% | Drug Manufacturers - Major |
 | Novo Nordisk | 105,8 | 3,0% | 19,7 | 1,4 | 334,0 | -21% | 5% | Biotechnology |
 | Sanofi | 96,2 | 4,0% | 13,4 | 0,4 | 77,1 | -12% | 4% | Drug Manufacturers - Major |
 | AstraZeneca | 93,4 | 3,3% | 16,7 | 1,1 | 6 438,0 | -21% | 2% | Drug Manufacturers - Major |
| GlaxoSmithKline | 88,0 | 4,8% | 0,1 | 0,9 | 1 593,0 | -12% | 4% | Drug Manufacturers - Major |
 | Bayer Aktiengesellschaft | 51,6 | 5,1% | 7,4 | 1,0 | 55,3 | -6% | 76% | Drug Manufacturers - Major |
| EssilorLuxottica | 48,4 | 1,8% | 23,0 | 0,4 | 110,4 | -13% | 17% | Medical Instruments & Supplies |
| MERCK Kommanditgesellschaft auf Aktien | 41,0 | 1,4% | 12,6 | 0,3 | 92,9 | -12% | 11% | Drug Manufacturers - Specialty & Generic |
| Siemens Healthineers | 37,7 | 1,9% | 20,3 | - | 37,9 | -16% | 5% | Diagnostics & Research |
 | Koninklijke Philips | 34,7 | 2,2% | 20,6 | 1,4 | 37,8 | -23% | 6% | Diagnostics & Research |
| Fresenius KGaA | 26,3 | 1,7% | 13,0 | 0,5 | 47,4 | -19% | 50% | Medical Care |
| Alcon | 25,6 | 0% | - | - | 58,0 | -7% | 10% | Medical Instruments & Supplies |
| Lonza Group | 22,0 | 0,8% | 43,8 | 1,3 | 327,0 | -25% | 5% | Diagnostics & Research |
| Fresenius Medical Care KGaA | 21,5 | 1,6% | 16,0 | 1,3 | 68,3 | -19% | 34% | Medical Care |
| Coloplast | 21,3 | 2,1% | 33,5 | 1,1 | 748,0 | -24% | 2% | Medical Instruments & Supplies |
| Smith & Nephew | 16,7 | 1,6% | 17,0 | 0,4 | 1 725,0 | -28% | 1% | Medical Devices |
 | Grifols | 15,1 | 1,2% | 21,2 | 0,4 | 24,8 | -13% | 9% | Biotech |
 | UCB | 13,7 | 1,7% | 15,3 | 0,5 | 72,4 | -10% | 13% | Biotechnology |
| Sonova Holding | 13,1 | 1,3% | 32,4 | 0,6 | 224,7 | -36% | 5% | Medical Instruments & Supplies |
| Sartorius Stedim Biotech | 12,7 | 0,4% | 49,3 | 0,6 | 138,1 | -42% | 2% | Life Science Equipment |
| Straumann Holding | 12,3 | 0,6% | 39,0 | 1,1 | 858,0 | -32% | 4% | Medical Instruments & Supplies |
| Novozymes | 11,6 | 1,6% | 25,7 | 1,0 | 303,7 | -14% | 20% | Biotechnology |
Moyennes capitalisations boursières4 (10 Md€ > Cap. ≥ 2 Md€
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Genmab | 9,9 | 0% | 38,8 | 0,5 | 1 201,0 | -35% | 3% | Biotechnology |
| Ipsen | 9,5 | 0,9% | 16,3 | 0,5 | 114,8 | -14% | 36% | Drug Manufacturers - Specialty & Generic |
| bioMérieux | 8,8 | 0,5% | 33,0 | 0,4 | 74,5 | -29% | 11% | Diagnostics & Research |
| QIAGEN | 8,2 | 0% | 24,2 | 0,3 | 35,8 | -19% | 3% | Diagnostics & Research |
| Vifor Pharma | 8,2 | 1,4% | 59,8 | 1,6 | 138,7 | -27% | 39% | Drug Manufacturers - Specialty & Generic |
| Carl Zeiss Meditec | 7,8 | 0,6% | 43,2 | 0,2 | 87,2 | -34% | 9% | Medical Instruments & Supplies |
 | Recordati Industria Chimica e Farmaceutica | 7,4 | 2,5% | 22,9 | 0,2 | 36,2 | -24% | 6% | Drug Manufacturers - Major |
| Demant | 6,9 | 0% | 28,8 | 0,9 | 205,0 | -14% | 55% | Medical Instruments & Supplies |
| H. Lundbeck | 6,7 | 4,7% | 13,9 | 0,9 | 252,6 | 0% | 89% | Drug Manufacturers - Specialty & Generic |
| ORPEA | 6,6 | 1,2% | 25,1 | 0,8 | 102,3 | -18% | 22% | Long-Term Care Facilities |
| Eurofins Scientific | 6,4 | 0,6% | 19,0 | 0,9 | 361,4 | -17% | 36% | Diagnostics & Research |
| Galapagos | 6,2 | 0% | -48,2 | 1,4 | 112,8 | -37% | 2% | Biotechnology |
| DiaSorin | 5,6 | 0,9% | 33,9 | 0,4 | 103,3 | -34% | 4% | Diagnostics & Research |
| NMC Health | 5,6 | 0,7% | 20,4 | 1,0 | 2 418,0 | -13% | 81% | Medical Care |
| GN Store Nord | 5,5 | 0,4% | 26,6 | 0,9 | 315,2 | -28% | 10% | Medical Devices |
 | Swedish Orphan Biovitrum | 5,2 | 0% | 16,0 | 1,0 | 182,1 | -12% | 65% | Drug Manufacturers - Specialty & Generic |
| Elekta | 4,6 | 1,1% | 29,9 | 1,1 | 128,1 | -24% | 4% | Medical Instruments & Supplies |
| argenx | 4,6 | 0% | -65,7 | 1,0 | 123,2 | -56% | 1% | Biotechnology |
| Amplifon | 4,6 | 0,7% | 33,7 | 0,6 | 20,9 | -36% | 6% | Medical Instruments & Supplies |
| Hikma Pharmaceuticals | 4,6 | 2,3% | 12,6 | 0,6 | 1 733,5 | -19% | 21% | Drug Manufacturers - Specialty & Generic |
 | Orion Oyj | 4,4 | 4,8% | 20,2 | 0,8 | 31,4 | -28% | 13% | Drug Manufacturers - Specialty & Generic |
| Lifco | 4,2 | 0,9% | 27,3 | 0,5 | 503,0 | -40% | 1% | Medical Instruments & Supplies |
| Getinge | 3,8 | 0,7% | 23,2 | 1,3 | 146,9 | -49% | 3% | Medical Instruments & Supplies |
| Evotec | 3,7 | 0% | 70,3 | 1,3 | 24,6 | -42% | 5% | Drug Manufacturers - Specialty & Generic |
| BTG | 3,6 | 0% | 18,5 | -0,1 | 834,0 | -44% | 2% | Biotechnology |
| Abcam | 3,3 | 0,9% | 51,5 | 0,7 | 1 435,0 | -30% | 11% | Biotechnology |
| Dechra Pharmaceuticals | 3,2 | 1,0% | 0,3 | 0,5 | 2 816,0 | -29% | 13% | Drug Manufacturers - Major |
| Convatec Group | 3,1 | 3,1% | 8,9 | 1,2 | 142,0 | -20% | 69% | Medical Instruments & Supplies |
| Ambu | 3,0 | 0,4% | 31,9 | 1,5 | 92,5 | -8% | 202% | Medical Devices |
| MorphoSys | 2,9 | 0% | -40,7 | 1,2 | 91,9 | -17% | 36% | Biotechnology |
| Almirall | 2,7 | 1,3% | 28,7 | 0,1 | 15,5 | -30% | 16% | Biotechnology |
| Korian | 2,7 | 1,8% | 23,3 | 0,2 | 32,9 | -17% | 13% | Long-Term Care Facilities |
| Tecan Group | 2,7 | 0,8% | 34,6 | 0,7 | 250,0 | -28% | 2% | Medical Devices |
| Idorsia | 2,4 | 0% | -5,9 | 1,6 | 20,5 | -26% | 38% | Biotechnology |
| Mediclinic International | 2,4 | 2,6% | 0,1 | 1,7 | 294,1 | 0% | 87% | Medical Care |
| ALK-Abelló | 2,3 | 0% | -254,3 | 0,0 | 1 554,0 | -43% | 5% | Biotechnology |
| Galenica | 2,2 | 3,4% | 16,6 | 0,6 | 49,8 | -15% | 18% | Biotechnology |
| UDG Healthcare | 2,1 | 1,9% | 14,8 | 0,8 | 756,5 | -28% | 13% | Medical Distribution |
| Gerresheimer | 2,0 | 1,8% | 11,4 | 0,8 | 65,0 | -21% | 24% | Medical Instruments & Supplies |
Petites capitalisations boursières4 (2 Md€ > Cap. ≥ 300 M€)
| Société | Cap.1 | Rdt. % | PER2 | Bêta | Cours | +bas3 | +haut3 | Industrie | |
|---|---|---|---|---|---|---|---|---|---|
| Vitrolife | 1,9 | 0,5% | 56,7 | 0,8 | 185,0 | -39% | 23% | Biotechnology |
| Genus | 1,9 | 1,0% | 0,3 | 1,0 | 2 618,0 | -20% | 15% | Biotechnology |
| RHÖN-KLINIKUM Aktiengesellschaft | 1,8 | 1,1% | 33,4 | 0,6 | 26,4 | -20% | 2% | Medical Care |
| Clinigen Group | 1,5 | 0,6% | 0,4 | 0,7 | 1 012,0 | -29% | 6% | Medical Distribution |
| Virbac | 1,4 | 0% | 22,4 | 0,4 | 172,0 | -39% | 9% | Drug Manufacturers - Major |
| Ypsomed Holding | 1,4 | 0,4% | 26,6 | 0,9 | 130,6 | -15% | 16% | Medical Devices |
| Siegfried Holding | 1,3 | 0,7% | 26,6 | 0,7 | 348,0 | -9% | 35% | Drug Manufacturers - Specialty & Generic |
| Fagron | 1,3 | 0,7% | 19,5 | 0,8 | 17,9 | -25% | 2% | Drug Manufacturers - Specialty & Generic |
| Cosmo Pharmaceuticals | 1,2 | 0% | -27,0 | 1,4 | 91,0 | -16% | 56% | Drug Manufacturers - Major |
| Faes Farma | 1,1 | 1,1% | 20,3 | 0,6 | 4,2 | -30% | 2% | Medical Instruments & Supplies |
| Arjo | 1,1 | 1,3% | 19,3 | - | 42,4 | -38% | 2% | Medical Devices |
| Mithra Pharmaceuticals | 0,9 | 0% | - | 0,9 | 24,3 | -25% | 54% | Drug Manufacturers - Specialty & Generic |
| Drägerwerk KGaA | 0,8 | 0,3% | 16,7 | 0,3 | 41,4 | -6% | 4% | Medical Devices |
| Recipharm | 0,8 | 1,0% | 22,6 | 1,4 | 118,2 | -8% | 42% | Biotechnology |
| Oncopeptides | 0,8 | 0% | -22,0 | 0,4 | 163,6 | -33% | 28% | Biotechnology |
| BioGaia | 0,7 | 0,9% | 37,2 | 0,9 | 433,0 | -29% | 14% | Drug Manufacturers - Specialty & Generic |
| Advanced Medical Solutions Group | 0,7 | 0,4% | 0,3 | 0,9 | 299,0 | -17% | 25% | Medical Instruments & Supplies |
| Genfit | 0,7 | 0% | -13,4 | 1,3 | 17,9 | -13% | 39% | Biotechnology |
| Stratec | 0,7 | 1,4% | 90,5 | 1,1 | 57,8 | -25% | 33% | Medical Devices |
| CellaVision | 0,7 | 0,5% | 66,5 | 1,8 | 300,0 | -44% | 15% | Diagnostics & Research |
| Biotage | 0,7 | 1,4% | 32,5 | 0,8 | 112,1 | -13% | 29% | Medical Instruments & Supplies |
| Bavarian Nordic | 0,7 | 0% | -112,2 | 1,0 | 156,0 | -25% | 30% | Biotechnology |
| Boiron | 0,7 | 3,9% | 7,7 | 0,8 | 37,7 | -1% | 95% | Drug Manufacturers - Major |
| Vectura Group | 0,6 | 0% | 0,1 | 1,0 | 88,0 | -25% | 2% | Drug Manufacturers - Major |
| Oxford BioMedica | 0,6 | 0% | -10 285,7 | -0,1 | 720,0 | -19% | 43% | Biotechnology |
| Biocartis Group | 0,6 | 0% | - | 1,8 | 10,7 | -10% | 19% | Diagnostics & Research |
| Medartis Holding | 0,6 | 0% | 146,3 | - | 58,5 | -11% | 44% | Medical Devices |
| Hansa Biopharma | 0,6 | 0% | - | 2,5 | 168,5 | -5% | 80% | Biotechnology |
| Karo Pharma | 0,6 | 0% | 19,5 | 0,2 | 39,7 | -27% | 14% | Biotechnology |
| Guerbet | 0,6 | 1,8% | 14,5 | 0,8 | 47,8 | -4% | 37% | Medical Devices |
| Attendo | 0,6 | 1,5% | 8,7 | 0,4 | 40,0 | -2% | 122% | Medical Care |
| Zealand Pharma | 0,6 | 0% | -9,6 | 1,3 | 137,9 | -43% | 8% | Biotechnology |
| Cellectis | 0,6 | 0% | -6,1 | 1,3 | 13,2 | -9% | 104% | Biotechnology |
| Spire Healthcare Group | 0,5 | 2,8% | 0,1 | 2,0 | 119,6 | -20% | 117% | Medical Care |
| DBV Technologies | 0,5 | 0% | -2,6 | 1,0 | 14,8 | -49% | 198% | Biotechnology |
| Eckert & Ziegler Strahlen- und Medizintechnik | 0,5 | 1,2% | 34,2 | 0,8 | 97,0 | -62% | 11% | Medical Devices |
| COLTENE Holding | 0,5 | 3,3% | 19,0 | 0,7 | 87,5 | -9% | 42% | Medical Instruments & Supplies |
| Xvivo Perfusion | 0,5 | 0% | 116,4 | 0,3 | 195,0 | -43% | 5% | Medical Devices |
| Pharming Group | 0,5 | 0% | 12,3 | 1,7 | 0,7 | -14% | 106% | Biotechnology |
| LNA Santé | 0,4 | 0,8% | 21,7 | 0,7 | 45,2 | -8% | 28% | Long-Term Care Facilities |
| Pharma Mar | 0,4 | 0% | - | 1,3 | 1,8 | -52% | 34% | Biotechnology |
| Ion Beam Applications | 0,4 | 0% | - | 1,8 | 13,9 | -36% | 83% | Medical Devices |
| Alliance Pharma | 0,4 | 2,1% | 0,2 | 0,7 | 70,5 | -16% | 45% | Drug Manufacturers - Specialty & Generic |
| Innate Pharma | 0,4 | 0% | 116,5 | 0,1 | 5,6 | -22% | 67% | Biotechnology |
| Probi | 0,4 | 0% | 23,0 | 1,3 | 330,5 | -4% | 36% | Biotechnology |
| EL.En. | 0,3 | 2,2% | 16,7 | 0,8 | 17,9 | -33% | 67% | Medical Devices |
| Indivior | 0,3 | 0% | 8,2 | 1,0 | 41,1 | -49% | 855% | Drug Manufacturers - Specialty & Generic |
| Basilea Pharmaceutica | 0,3 | 0% | -15,8 | 1,8 | 34,1 | -2% | 104% | Biotechnology |
| Camurus | 0,3 | 0% | -10,6 | 1,1 | 69,1 | -21% | 61% | Biotechnology |
1 Ou contre-valeur en € d’après la parité en vigueur 2 Prévision 3 Ecart par rapport au +bas/haut à 52 semaines
4 Les données peuvent comporter des inexactitudes : ne prenez pas de décisions d’investissement sur leur seule base.
Déposez vos remarques et suggestions sur les forums : Screeners de l’IH.